A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ALS-L1023 in Non-Alcoholic Fatty Liver Disease

Article Gastroenterology & Hepatology

Prevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction-associated fatty liver disease in Korea

Mimi Kim et al.

Summary: This study evaluated the prevalence of advanced fibrosis in metabolic dysfunction-associated fatty liver disease (MAFLD) patients. The results showed that the prevalence of advanced fibrosis in MAFLD patients was 3.0%.

LIVER INTERNATIONAL (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis

Jonathan G. Stine et al.

Summary: The meta-analysis showed that a >= 30% relative decline in MRI-PDFF is associated with higher odds of histologic response and NASH resolution. These results support the use of MRI-PDFF in monitoring treatment response in early-phase NASH trials and provide helpful data for sample-size estimation for histology-based assessment.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)

添加到收藏夹

Article Plant Sciences

The herbal extract ALS-L1023 from Melissa officinalis reduces weight gain, elevated glucose levels and β-cell loss in Otsuka Long-Evans Tokushima fatty rats

Yujin Shin et al.

Summary: The study showed that ALS-L1023, extracted from lemon balm, could reduce weight gain, inhibit hyperglycemia, restore beta-cell mass, decrease lipid accumulation in the liver and skeletal muscle, regulate the expression of fatty acid-oxidizing enzymes in the liver and muscle, and alleviate pancreatic inflammation.

JOURNAL OF ETHNOPHARMACOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Fibrosis Burden of Missed and Added Populations According to the New Definition of Metabolic Dysfunction-Associated Fatty Liver

Huiyul Park et al.

Summary: With the proposal of the new MAFLD definition, the added population (MAFLD-only group) shows a higher metabolic and fibrosis burden compared to those in the missed population (NAFLD-only group).

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Review Chemistry, Medicinal

Antiangiogenic Drugs in NASH: Evidence of a Possible New Therapeutic Approach

Paola Orlandi et al.

Summary: Non-alcoholic fatty liver disease is the most common liver disorder worldwide, with its progressive form, NASH, being a growing cause of liver cirrhosis and hepatocellular carcinoma. Angiogenesis is a key mechanism influencing the progression of these diseases, suggesting that antiangiogenic drugs may help to stop or slow the progression.

PHARMACEUTICALS (2021)

添加到收藏夹

Article Gastroenterology & Hepatology